Corline Biomedical (Q2 Review): Early stages of the Globe ramp-up - Redeye
Bildkälla: Stockfoto

Corline Biomedical (Q2 Review): Early stages of the Globe ramp-up - Redeye

Redeye provides an update following Corline’s Q2 2026 report. Sales came in below expectations, while cost control remains solid. We do not draw any major conclusions from the lower-than-expected sales and continue to see a strong long-term outlook. In this research update, we make some adjustments to our short-term sales estimates and introduce a new fair value, which suggests that the Corline share is currently attractively priced.

Redeye provides an update following Corline’s Q2 2026 report. Sales came in below expectations, while cost control remains solid. We do not draw any major conclusions from the lower-than-expected sales and continue to see a strong long-term outlook. In this research update, we make some adjustments to our short-term sales estimates and introduce a new fair value, which suggests that the Corline share is currently attractively priced.
Börsvärldens nyhetsbrev